2 results
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMORecruiting
The aim of the current study is to assess the potential time- and cost-savings of fluoroscopically aided reductions of dislocated DRFs in adult patients.